| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Advisory Committee (AdCom) example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Rare Diseases | ||
Advisory Committee (AdCom) example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Rare Diseases | ||
Advisory Committee (AdCom) example | Phase 3 | — | Subscribe to access the data. | Cell Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Capricor Therapeutics, Inc.$6.95
-0.09 (-1.36%)
C 53Pipeline Score Overvalued Pharma · Clinical
Market Cap
1.67 B
EPS
-2.31
P/E Ratio
-
Value Trade
18.26 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
27.38 M
Operating CF
-29.25 M
Total Assets
326.28 M
Total Liabilities
47.58 M
Equity
278.70 M
D/E Ratio
12,345
-0.82 %
Week
-19.29 %
1 Month
0.59 %
3 Month
412.79 %
6 Month
644.07 %
5 Year
-96.39 %
All Time
Cash Data
Cash Position
278.61 M
Monthly Burn
9.75 M
Runway
26.1 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.06 M
52 Week Range
4.30 - 40.37
% held by Insiders
9.67 %
% held by Institutions
58.3 %
Enterprise Value
1.41 B
Total Shares
57.94 M
Short %
37.5 %
Float Shares
41.55 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Capricor Therapeutics, Inc.
782Total events
12Upcoming
209Tier-1 (high impact)
2009 – 2027Coverage
Upcoming catalysts 2
TBD
T1AdCom Scheduled
Subscribe to view catalyst details
TBD
T1PDUFA Date
Subscribe to view catalyst details
Event history 2
TBD
◆AdCom Briefing DocsDeramiocelFiledAdvisory Committee
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-31 | StealthX™ exosome-based vaccine | phase 1 data readout | Phase 1 | — | – | – | – |
2026-03-31 | StealthX™ exosome-based vaccine | phase 1 data readout | Phase 1 | — | – | – | – |
2026-03-31 | StealthX™ exosome-based vaccine | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
C53
Pipeline Score $452M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 82%
Micro Cap (rank 165 of 913)
Percentile RankCapricor Therapeutics, Inc. carries a moderate pipeline score (53/100), with $1.1B risk-adjusted pipeline value, led by Cenderitide in Heart Failure (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cenderitide Small molecule | Heart Failure | Phase 2 | NCT02603614 | 9% | $551M | COMPLETED | 22 | - | - | Mar 1, 2016 | - | Feb 10, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Deramiocel PriorityRMATOrphan+1 | Duchenne Muscular Dystrophy | Phase 3 | 2026-06-26 | PUL 2.0 year-over-year decline attenuated to approximately 1 point; mean total-score decline of less than 5 points over five years; project to approximately 12 points over five years; stable over the full five-year period; modeled decline of approximately 3.2% per year; p=0.03; p=0.04 Read More | Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference Read More | |
Deramiocel PriorityRMATOrphan+1 | Duchenne Muscular Dystrophy | Phase 3 | 2026-06-26 | PUL 2.0 year-over-year decline attenuated to approximately 1 point; mean total-score decline of less than 5 points over five years; project to approximately 12 points over five years; stable over the full five-year period; modeled decline of approximately 3.2% per year; p=0.03; p=0.04 Read More | Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference Read More | |
Deramiocel PriorityRMATOrphan+1 | Duchenne Muscular Dystrophy | Phase 3 | 2026-06-26 | PUL 2.0 year-over-year decline attenuated to approximately 1 point; mean total-score decline of less than 5 points over five years; project to approximately 12 points over five years; stable over the full five-year period; modeled decline of approximately 3.2% per year; p=0.03; p=0.04 Read More | Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CAPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CAPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CAPR▲ +9%on this news
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Capricor Therapeutics has provided an update ahead of the FDA Advisory Committee meeting regarding its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. The company emphasizes its transparency with the FDA and highlights positive results from the Phase 3 HOPE-3 trial. However, there are concerns about the reliance on outdated analysis materials.
Read more →CAPRCapricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics announced an upcoming FDA Advisory Committee meeting on July 29, 2026, to review its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. The application is supported by positive results from Phase 2 and Phase 3 trials. The company aims to engage with the FDA and the DMD community during this critical review process.
Read more →CAPR▼ -13%on this news· ran to -24% by day 3shared move
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Capricor Therapeutics announced positive five-year data from its HOPE-2 Open-Label Extension study of Deramiocel for Duchenne Muscular Dystrophy. The study demonstrated a significant attenuation of disease progression and stable cardiac function. These findings will be presented at the PPMD 2026 Annual Conference, alongside results from the successful HOPE-3 Phase 3 trial. The company is preparing for a potential FDA approval by August 2026.
Read more →CAPRCapricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics announced its participation in several upcoming investor conferences, including the Goldman Sachs 47th Annual Global Healthcare Conference and the Oppenheimer CNS and Neuro-Muscular Summit. The company's lead product, Deramiocel, is in late-stage development for Duchenne muscular dystrophy and aims to preserve cardiac and skeletal muscle function. The events will provide opportunities for management to engage with investors and discuss the company's advancements.
Read more →CAPRCapricor Therapeutics Expands Commercial Leadership Team
Capricor Therapeutics has appointed Michael Maurer as Chief Commercial Officer to enhance its commercial leadership team. With extensive experience in rare disease commercialization, Maurer will support the launch readiness of Deramiocel, an investigational therapy for Duchenne muscular dystrophy. His role will focus on market access, patient support, and distribution strategy as the company approaches its PDUFA date.
Read more →CAPRCapricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Capricor Therapeutics reported its first quarter 2026 financial results, highlighting the ongoing FDA review of its BLA for Deramiocel, with a target action date of August 22, 2026. The HOPE-3 Phase 3 trial successfully met its primary endpoint, and the company is preparing for a potential commercial launch. However, Capricor has filed a lawsuit against NS Pharma regarding a distribution agreement, which may affect its operations.
Read more →CAPRCapricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy -Complaint outlines its distribution partner's failure to prepare for launch of DMD therapy; Capricor seeks
Capricor Therapeutics has initiated legal action against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary to address failures in their distribution agreement for Deramiocel, an investigational therapy for Duchenne muscular dystrophy (DMD). The lawsuit highlights issues related to pricing flaws that could restrict patient access to this critical treatment. Capricor aims to ensure that Deramiocel reaches patients, particularly as the FDA has granted it Priority Review status. The company is working towards commercial readiness for a responsible launch pending FDA approval.
Read more →CAPR▲ +8.4%on this newsshared move
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics is set to release its financial results for the first quarter of 2026 on May 12, alongside a corporate update. Management will host a conference call for investors to discuss these developments. The company continues to advance its lead product candidate, Deramiocel, and is focusing on exosome technology for treating rare diseases. The results are anticipated with interest from stakeholders, reflecting the company's ongoing efforts in the biotech sector.
Read more →CAPRCapricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
Capricor Therapeutics presented promising results from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy at the AAN 2026 Annual Meeting. The data indicated a statistically significant improvement in upper limb function and a meaningful impact on disease progression. With a BLA under FDA review, Capricor aims to expedite access to this potential therapy for patients.
Read more →CAPR▼ -8.7%on this news
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Capricor Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of approximately $318.1 million. The company is focused on the potential FDA approval of Deramiocel for Duchenne muscular dystrophy, with a PDUFA target date set for August 22, 2026. Despite reporting zero revenues for the quarter, recent clinical data supports the therapeutic's promise.
Read more →CAPR▼ -8.7%on this news
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics presented new data from the Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy at the 2026 MDA Conference. The findings highlight significant functional benefits for patients, particularly in daily activities. The company is currently awaiting FDA approval, with a target action date of August 22, 2026.
Read more →CAPR▲ +9%on this newsshared move
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrop
Capricor Therapeutics has announced the resumption of the FDA review for its Biologics License Application (BLA) for Deramiocel, a therapy potential for Duchenne muscular dystrophy (DMD). This follows the lift of a prior Complete Response Letter, with a new target action date set for August 22, 2026. Capricor expresses confidence in the positive outcomes from their HOPE-3 trial and the potential for Deramiocel to become a first-in-class treatment, addressing critical skeletal and cardiac issues faced by DMD patients.
Read more →CAPR▲ +9.8%on this news· ran to +20% by day 3shared move
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
Capricor Therapeutics announced it will release its financial results for Q4 and full year 2025 on March 12, 2026. A conference call will follow at 4:30 p.m. ET. The company is focused on developing cell and exosome-based therapies, with its lead candidate, Deramiocel, in late-stage development for Duchenne muscular dystrophy.
Read more →CAPRCapricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Capricor Therapeutics announced that results from its Phase 3 HOPE-3 clinical study of Deramiocel for Duchenne muscular dystrophy will be presented at the 2026 MDA Clinical and Scientific Conference. The presentation highlights the growing clinical evidence supporting Deramiocel's potential benefits for patients. Capricor is also advancing its regulatory efforts, including a recent submission to the FDA.
Read more →CAPRCapricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Capricor Therapeutics has provided a regulatory update on its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. Following the FDA's review of the Phase 3 HOPE-3 study data, the agency requested the full clinical study report to address a Complete Response Letter. Capricor plans to submit the requested materials in February 2026, aiming to support the continued review of the BLA.
Read more →CAPRCapricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Capricor Therapeutics is set to host a webinar in collaboration with Parent Project Muscular Dystrophy to discuss the encouraging topline results from the Phase 3 HOPE-3 trial of Deramiocel, a cell therapy for Duchenne muscular dystrophy. The event is scheduled for December 17, 2025, and aims to inform patients and families about the findings and their implications for future regulatory discussions. Deramiocel has demonstrated immunomodulatory and anti-fibrotic effects, positioning it as a potential treatment option for DMD.
Read more →CAPR▲ +5.9%on this news
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Capricor Therapeutics has announced the pricing of a public offering of 6,000,000 shares of common stock at $25.00 per share, aiming to raise $150 million. The proceeds are earmarked for the development and manufacturing of their product candidates, primarily Deramiocel for Duchenne muscular dystrophy. The offering is expected to close around December 8, 2025, subject to customary conditions. Joint book-running managers for the offering include Piper Sandler and Oppenheimer & Co.
Read more →CAPR▼ -15.2%on this newsshared move
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Capricor Therapeutics announced a proposed underwritten public offering of its common stock to support the development of its product candidates and general corporate purposes. The offering includes an option for underwriters to purchase additional shares. While the offering aims to bolster funding for its promising lead candidate, Deramiocel, the completion of the offering is uncertain and subject to market conditions. Additionally, there are inherent risks associated with market fluctuations and regulatory approvals.
Read more →CAPR▲ +371.1%on this newsshared move
Capricor Therapeutics, Inc. Nasdaq: CAPR
Capricor Therapeutics reported positive results from its pivotal Phase 3 HOPE-3 trial for Deramiocel, a potential first-in-class treatment for Duchenne muscular dystrophy (DMD). The study met its primary endpoint (PUL v2.0) and key secondary endpoint (LVEF), both achieving statistical significance. Deramiocel also demonstrated a favorable safety profile, aligning with prior clinical experiences. Following these results, Capricor plans to submit a response to the FDA based on the HOPE-3 data.
Read more →CAPR▲ +371.1%on this newsshared move
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the p
Capricor Therapeutics announced positive topline results from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne muscular dystrophy. The study showed statistically significant improvements in both skeletal and cardiac functions, with a 54% slowing of disease progression as measured by the Performance of Upper Limb (PUL) scale. These findings may support the company's pursuit of regulatory approval, particularly following prior FDA guidance suggesting that the results from HOPE-3 could be sufficient. The trial involved 106 participants and maintained a favorable safety profile consistent with previous studies.
Read more →CAPR▼ -19.3%on this news
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
Capricor Therapeutics recently presented new data on a scalable framework for loading therapeutic oligonucleotides into exosomes at the AAEV 2025 Annual Meeting. This innovative approach demonstrated efficient loading of small interfering RNAs (siRNA) and phosphorodiamidate morpholino oligomers (PMOs) into engineered exosomes. The findings suggest that integrating scale-up and scale-out strategies can yield larger quantities of loaded exosomes, crucial for advancing clinical applications. The company's commitment to enhancing its exosome-based platform reflects its focus on delivering transformative treatments for various diseases.
Read more →CAPR▲ +11.5%on this news
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Capricor Therapeutics reported its third quarter 2025 financial results, highlighting a pivotal moment as it approaches topline results from the HOPE-3 Phase 3 trial for Deramiocel, aimed at treating Duchenne muscular dystrophy. The company noted a cash position of approximately $98.6 million, but reported zero revenues for the quarter, leading to a net loss of $24.6 million. Despite the financial challenges, Capricor remains focused on advancing Deramiocel toward potential approval and commercialization.
Read more →CAPRCapricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
Johnson Fistel, PLLP has announced an investigation into potential legal claims on behalf of Capricor Therapeutics, Inc. shareholders due to alleged misconduct by the company's executives. This investigation is focused on actions that may have negatively impacted the company and its investors. Shareholders who have held shares since before October 9, 2024, are encouraged to reach out for more information regarding their rights. The firm is known for representing shareholders in legal actions and has had significant recoveries in the past.
Read more →CAPR▼ -6.8%on this newsshared move
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
Capricor Therapeutics has published a peer-reviewed study in Biomedicines detailing the anti-fibrotic mechanism of action of its investigational therapy, Deramiocel. The study introduces a validated potency assay that supports quality control in late-stage development. Findings indicate that cardiosphere-derived cells can modulate fibrotic processes, consistent with previous clinical data. Deramiocel is currently undergoing evaluation in the Phase 3 HOPE-3 trial for Duchenne muscular dystrophy.
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Capricor Therapeutics (NASDAQ: CAPR) will announce its financial results for the third quarter of 2025 on November 10, followed by a conference call and webcast. The company is focused on transformative therapies, including its lead product, Deramiocel, which is in late-stage development for Duchenne muscular dystrophy. Their innovative approaches and recent corporate updates highlight commitment to advancing treatments for rare diseases.
Read more →CAPRCAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. due to a class action complaint related to misleading statements about its drug deramiocel. The investigation centers on whether the company's board violated fiduciary duties following a Complete Response Letter from the FDA, which denied the Biologics License Application citing insufficient evidence of effectiveness. Consequently, Capricor's stock price experienced a substantial decline after the announcement of the CRL.
Read more →CAPR▲ +5.3%on this news· ran to +16% by day 3
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
Capricor Therapeutics has provided a regulatory update on its investigational cell therapy, Deramiocel, for Duchenne muscular dystrophy following a Type A meeting with the FDA. The meeting clarified the regulatory strategy and emphasized the importance of upcoming HOPE-3 trial data for potential approval. Despite a recent Complete Response Letter, the company remains optimistic about advancing Deramiocel toward market approval.
Read more →CAPRCAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating Capricor Therapeutics on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by Capricor's board. The complaint follows a Complete Response Letter from the FDA that denied Capricor's Biologics License Application for their drug deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy. As a result of the FDA's decision, Capricor's stock price fell sharply from $11.40 to $7.64 within a single day.
Read more →CAPR▼ -5%on this newsshared move
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit
A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly misleading investors regarding their lead cell therapy candidate, deramiocel. This lawsuit comes after Capricor's stock plummeted following a Complete Response Letter from the FDA, which cited deficiencies in the drug's evidence of effectiveness. Investors are encouraged to contact the law firm Bragar Eagel & Squire for assistance if they suffered losses during the class period. The firm is conducting outreach to potential lead plaintiffs ahead of the September 15 deadline.
Read more →CAPRCapricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
Capricor Therapeutics has responded to the FDA's public posting of a Complete Response Letter for its investigational therapy, Deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy. The company was unaware of the posting and is focused on addressing the FDA's concerns. Capricor plans to share its response and is awaiting further guidance from the FDA following a recent meeting.
Read more →CAPRCapricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion
Capricor Therapeutics, Inc. is facing a class action lawsuit from investors who bought securities between October 9, 2024, and July 10, 2025. This lawsuit claims that Capricor misled investors by failing to disclose adverse safety and efficacy data from their Phase 2 trial. Notably, the company's stock has experienced significant declines following key FDA announcements, which have raised concerns over the approval of their drug, deramiocel. Investors are urged to contact the Portnoy Law Firm to explore options for recovering their losses before the September 15, 2025 deadline.
Read more →CAPR▼ -5.8%on this newsshared move
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Capricor Therapeutics, Inc. is facing a securities fraud class action lawsuit filed by Bernstein Liebhard LLP on behalf of investors who purchased shares between October 9, 2024, and July 10, 2025. The lawsuit claims that the company and some of its senior officers misrepresented the four-year safety and efficacy data of deramiocel, their lead cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy. Investors interested in joining the class action must file papers by September 15, 2025.
Read more →CAPR▼ -5.8%on this newsshared move
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who acquired securities during a specified period. The complaint indicates that Capricor misled investors regarding the efficacy and safety data of its lead therapy candidate, deramiocel, while seeking FDA approval. Following the receipt of a Complete Response Letter from the FDA denying the Biologics License Application, Capricor's stock price dropped significantly. Investors are encouraged to contact the law firm for further information on their legal rights.
Read more →CAPR▲ +13.5%on this newsshared move
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion.
Capricor Therapeutics, Inc. is facing a class action lawsuit that includes allegations of misleading statements regarding the safety and efficacy of its drug, deramiocel. The lawsuit claims that Capricor failed to disclose critical information from its clinical trials, which contributed to significant declines in the company's stock price. Key events leading to the lawsuits include adverse outcomes from a mid-cycle FDA review and the subsequent denial of their Biologics License Application. Investors have until September 15, 2025, to file a lead plaintiff motion.
Read more →CAPR▲ +13.5%on this newsshared move
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPR
Capricor Therapeutics, Inc. is currently facing a class action lawsuit that alleges securities fraud related to its lead drug candidate, deramiocel, used for treating cardiomyopathy in Duchenne muscular dystrophy. The suit claims that misleading statements were made by the company's defendants regarding the drug's regulatory status, particularly after the FDA issued a Complete Response Letter denying the Biologics License Application due to insufficient evidence of effectiveness. Shareholders who experienced losses during the specified period can seek to become lead plaintiffs in this class action until September 15, 2025.
Read more →CAPRCAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder to investors of Capricor Therapeutics, Inc. about an upcoming deadline related to a class action lawsuit. The lawsuit, filed due to allegations of securities fraud, claims that the company misrepresented data from a critical clinical trial for its cell therapy candidate, deramiocel. Investors who purchased shares between October 9, 2024, and July 10, 2025, are encouraged to consider their legal rights and options. The deadline to file as a lead plaintiff in this case is September 15, 2025.
Read more →CAPRCapricor Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights – CAPR
Capricor Therapeutics, Inc. is embroiled in a class action securities lawsuit alleging that the company made misleading statements linked to its lead drug candidate, deramiocel. The suit claims that while Capricor provided optimistic information about securing FDA approval for the drug, it concealed adverse information regarding safety and efficacy from a clinical trial. The situation escalated when the FDA issued a Complete Response Letter rejecting the application, resulting in a sharp decline in the company's stock price. Investors affected between October 2024 and July 2025 are encouraged to participate in the lawsuit, with no costs for class members.
Read more →CAPRCapricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
Capricor Therapeutics has initiated a Phase 1 clinical trial for its StealthX™ exosome-based vaccine, marking a significant milestone in vaccine development. Funded by the NIH, the trial aims to evaluate the vaccine's safety and efficacy against SARS-CoV-2. The StealthX™ platform is designed to provide a more natural delivery system without adjuvants, potentially expanding its application across various therapeutic areas. Initial data from the trial is expected in early 2026.
Read more →CAPRCapricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR
Capricor Therapeutics, Inc. is facing a class action lawsuit alleging securities fraud concerning the misleading statements about its lead therapy candidate, deramiocel. Investors have been invited to contact The Gross Law Firm for potential lead plaintiff status. The lawsuit follows a Complete Response Letter from the FDA that denied the company's application for deramiocel due to insufficient evidence of effectiveness, resulting in a significant decline in CAPR's stock price. Shareholders have until September 15, 2025, to register for participation in the class action case.
Read more →CAPR▼ -13.8%on this newsshared move
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approval Capricor seeks to resu
Capricor Therapeutics has reported its second quarter 2025 financial results, revealing a net loss of $25.9 million and no revenue during the period. Despite the setback of receiving a Complete Response Letter (CRL), the company is preparing for a Type A meeting with the FDA to discuss its Biologics License Application for Deramiocel. The FDA has accepted all observations from their Pre-License Inspection, indicating progress towards regulatory approval. The company also highlighted the success of its StealthX program and remains committed to advancing its therapeutic platforms.
Read more →CAPR▲ +12.4%on this newsshared move
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
Capricor Therapeutics has announced a Type A meeting with the U.S. FDA to discuss the regulatory pathway for its Biologics License Application for Deramiocel, a cell therapy candidate aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy. The company has also rescheduled its Q2 financial results release to accommodate this meeting.
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
Capricor Therapeutics announced it will release its financial results for the second quarter of 2025 on August 13. A conference call and webcast will follow, providing an update on recent corporate developments. The company continues to advance its lead product candidate, Deramiocel, in late-stage development for Duchenne Muscular Dystrophy (DMD). Capricor has also secured an exclusive commercialization agreement for Deramiocel in the United States and Japan. However, future regulatory approvals and outcomes remain uncertain.
Read more →CAPRCapricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics will host a webinar on July 29, 2025, to discuss the status of its Biologics License Application for Deramiocel, a treatment for Duchenne Muscular Dystrophy. The event, in collaboration with Parent Project Muscular Dystrophy, will cover cardiomyopathy and allow community questions. Deramiocel is in late-stage development and shows promise in treating muscular dystrophies.
Read more →CAPRCAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: Investors With Large Losses in Capricor Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Capricor Therapeutics, Inc. is facing a securities class action lawsuit filed by Bernstein Liebhard LLP on behalf of investors who acquired its securities between October 2024 and July 2025. The lawsuit alleges misrepresentations regarding the four-year safety and efficacy results from the Phase 2 HOPE-2 trial of its lead therapy candidate, deramiocel, for cardiomyopathy related to Duchenne muscular dystrophy. Investors are being encouraged to participate in the lawsuit, with the deadline for lead plaintiff nominations set for September 15, 2025.
Read more →CAPR▼ -33%on this news
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 tr
Capricor Therapeutics (NASDAQ: CAPR) announced it received a Complete Response Letter from the FDA regarding its Biologics License Application for Deramiocel, intended for treating cardiomyopathy associated with Duchenne muscular dystrophy. The FDA stated that the application lacks sufficient evidence of effectiveness and requires additional clinical data. In response, Capricor plans to submit results from the ongoing Phase 3 HOPE-3 trial to address the concerns raised. The company remains committed to navigating the regulatory process to benefit the DMD community.
Read more →CAPR▲ +20.4%on this news· ran to +45% by day 3
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Capricor Therapeutics has provided a regulatory update on its Biologics License Application (BLA) for Deramiocel, aimed at treating Duchenne Muscular Dystrophy. The FDA has confirmed that an Advisory Committee meeting is not necessary and the application is under Priority Review with a target action date of August 31, 2025. Capricor has also presented promising four-year data showing sustained cardiac function from long-term treatment. The company is moving forward with plans for a late-cycle review meeting scheduled for mid-July.
Read more →CAPR▼ -30.8%on this newsshared move
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics has announced favorable results from the four-year HOPE-2 Open-Label Extension study, highlighting the efficacy and safety of Deramiocel for Duchenne Muscular Dystrophy (DMD). The treatment demonstrated significant preservation of cardiac function and a slowdown in skeletal muscle disease progression. The results, which will be presented at the PPMD Annual Conference, bolster expectations for regulatory approval as discussions with the FDA indicate no delays in the process. The positive outcomes of the study support continued progress towards making Deramiocel accessible to patients.
Read more →CAPRCapricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Capricor Therapeutics announced that the U.S. FDA has granted Orphan Drug Designation to its lead candidate, Deramiocel, for the treatment of Becker Muscular Dystrophy. This designation aims to broaden the potential application of the therapy within neuromuscular diseases. Additionally, the company is maintaining its schedule for the PDUFA date of August 31, 2025, for Deramiocel's Biologics License Application for Duchenne Muscular Dystrophy after a successful regulatory inspection. The advancement of Deramiocel highlights its potential benefits for patients suffering from these related conditions.
Read more →CAPR▼ -5.4%on this news
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
Capricor Therapeutics has reported significant regulatory advancements for its Duchenne Muscular Dystrophy (DMD) therapeutic candidate, Deramiocel. The FDA's Pre-License Inspection of its manufacturing facility was successfully completed, with noted observations that the company has addressed. The Biologics License Application remains under priority review, with a target action date set for August 31, 2025, and an Advisory Committee meeting scheduled for July 30, 2025. These steps position Capricor to potentially bring this much-needed therapy to the DMD community.
Read more →CAPRCapricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under prio
Capricor Therapeutics reported its financial results for the first quarter of 2025, indicating a revenue drop to $0 and a significant net loss of approximately $24.4 million. Despite these financial hurdles, the company remains optimistic as it continues to actively engage with the FDA regarding its BLA for deramiocel in treating Duchenne muscular dystrophy, with a PDUFA action date set for August 31, 2025. The company's cash position remains strong at about $145 million, expected to support operations through 2027. Additionally, preparations for an FDA advisory committee meeting and a Phase 1 trial for the StealthX vaccine are underway.
Read more →CAPRCapricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
Capricor Therapeutics announced the appointment of Dr. Michael Binks as Chief Medical Officer, effective immediately. Dr. Binks has over 25 years of experience in clinical development and considerable expertise in Duchenne muscular dystrophy (DMD). He will lead the advancement of Capricor's lead product candidate, deramiocel, currently in late-stage development. This strategic addition to the leadership team is intended to enhance the company's efforts in the rare disease space and aid in pipeline expansion opportunities.
Read more →CAPR▼ -29.1%on this news
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
Capricor Therapeutics announced that it will release its financial results for the first quarter of 2025 following the market close on May 13. A conference call and webcast will be held to discuss the results at 4:30 p.m. ET on the same day. The company continues to advance its lead product candidate, deramiocel, a cell therapy for Duchenne muscular dystrophy, and is leveraging its exosome technology for broader applications. This financial update reflects the company's ongoing commitment to transparency with stakeholders.
Read more →CAPR▼ -13.2%on this news· ran to -41% by day 3shared move
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Capricor Therapeutics has completed a mid-cycle review meeting with the FDA regarding its Biologics License Application for deramiocel, a therapy for Duchenne muscular dystrophy cardiomyopathy. The FDA reported no significant deficiencies in the application, confirming that the product is on track for a PDUFA action date of August 31, 2025. An advisory committee meeting is anticipated prior to this date, during which Capricor plans to present its efficacy and safety data. Deramiocel aims to be a transformative treatment option for patients with this severe condition.
Read more →CAPRCapricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Capricor Therapeutics announced it will present at the 2025 Piper Sandler Virtual Cardio Day, discussing advancements in its deramiocel program aimed at treating Duchenne muscular dystrophy (DMD). The event will include a fireside chat led by CEO Linda Marbán, highlighting general updates related to the company's regulatory and scientific progress. Deramiocel is currently in late-stage development but has not yet received regulatory approval for any indication.
Read more →CAPR▲ +5.3%on this news· ran to +24% by day 1
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramio
Capricor Therapeutics reported its fourth quarter and full year 2024 financial results, announcing significant progress towards commercializing deramiocel, a treatment for Duchenne cardiomyopathy. The FDA has accepted their Biologics License Application, with a decision action date set for August 31, 2025. The company has financial stability with over $150 million in reserves due to successful funding rounds. However, Capricor continues to face financial challenges, reflected in their net losses, along with rising operating expenses.
Read more →CAPRCapricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics has announced promising long-term data from its HOPE-2 clinical trial, showcasing the effectiveness of deramiocel in treating Duchenne muscular dystrophy (DMD). Results indicate a significant 52% reduction in disease progression over three years compared to an external comparator group. The data highlights a favorable safety profile with no new safety concerns, further affirming the potential for deramiocel to transform DMD treatment. The company awaits regulatory action from the FDA for its Biologics License Application by August 31, 2025.
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Capricor Therapeutics plans to announce its financial results for the fourth quarter and full year of 2024 on March 19, 2025, followed by a conference call and webcast. The company is focused on innovative cell and exosome-based therapeutics targeted at rare diseases, with its lead candidate, deramiocel, currently under late-stage development for Duchenne muscular dystrophy. While Capricor is committed to advancing its therapeutic platforms, it faces challenges related to regulatory approvals and the inherent risks of forward-looking statements.
Read more →CAPR▼ -5.7%on this newsshared move
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Capricor Therapeutics will participate in the Leerink Global Healthcare Conference 2025, where management will discuss their lead program, deramiocel, for treating Duchenne muscular dystrophy. The conference will occur from March 10 to 12, 2025, with Capricor's presentation scheduled for March 12. This event highlights the company's focus on advancing its innovative therapies and corporate updates for stakeholders. However, deramiocel remains an investigational drug pending regulatory approval.
Read more →CAPRCapricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy --FDA assigns PDUFA target action date of
Capricor Therapeutics announced that the FDA has accepted its Biologics License Application for deramiocel, a potential treatment for Duchenne muscular dystrophy (DMD) cardiomyopathy. The FDA has granted Priority Review and set a target action date of August 31, 2025. Notably, deramiocel, if approved, would be the first therapy to address this condition, which currently lacks approved treatments. The application is backed by clinical data from previous trials showing its potential efficacy in treating DMD cardiomyopathy.
Read more →CAPRCapricor Therapeutics to Participate in Upcoming Investor Conferences
Capricor Therapeutics, a biotechnology firm specializing in cell and exosome-based therapies, has announced its participation in several forthcoming investor conferences. During these events, the company plans to share updates on its lead product candidate, deramiocel, aimed at treating Duchenne muscular dystrophy (DMD). The events include the Oppenheimer 35th Annual Healthcare Life Sciences Conference and the Barclays 27th Annual Global Healthcare Conference. Progress in the development of deramiocel remains a significant focus for the company as it seeks to change the treatment landscape for rare diseases.
Read more →CAPR▲ +8.4%on this news
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -If approved, deramiocel would be first approved therapy for Duc
Capricor Therapeutics has completed the submission of its Biologics License Application (BLA) to the FDA for deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy. This submission allows for a potential milestone payment of $10 million from Nippon Shinyaku. The application is supported by clinical trial data indicating the therapy's positive impact on cardiac issues associated with DMD. If approved, deramiocel would be the first therapy approved for DMD, offering hope for patients suffering from this severe condition.
Read more →CAPRCapricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Capricor Therapeutics announced that its lead asset, deramiocel, received Orphan Drug and Advanced Therapy Medicinal Product (ATMP) designations from the European Medicines Agency (EMA) for treating Duchenne muscular dystrophy (DMD). These designations provide Capricor with significant benefits, including market exclusivity in Europe and regulatory support for development. The company is also progressing with its rolling Biologics License Application (BLA) with the US FDA, aiming for full approval by the end of 2024. Deramiocel is targeting a severe genetic disorder with limited treatment options, affecting thousands of patients.
Read more →CAPR▼ -6.6%on this news
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy
Capricor Therapeutics announced its financial results for the third quarter of 2024, highlighting significant progress in the development of deramiocel for Duchenne muscular dystrophy (DMD). The company is moving towards commercialization with an ongoing Biologics License Application (BLA) submission expected to conclude by year-end. Despite a reported net loss of approximately $12.6 million, Capricor has strengthened its financial position to support manufacturing scaling. The StealthX platform continues to be a focus for advancing therapeutic developments.
Read more →CAPR▼ -7.4%on this newsshared move
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
Capricor Therapeutics announced the presentation of new preclinical data on its StealthX™ exosome platform at the 2024 American Association of Extracellular Vesicles Annual Meeting. This research emphasizes the potential of using exosomes to deliver phosphorodiamidate morpholino oligomers for the treatment of Duchenne muscular dystrophy (DMD). The company continues to develop its exosome technology, which aims to improve cellular uptake and efficacy of therapies. Capricor remains focused on leveraging partnerships to enhance its innovative treatment approaches for rare diseases.
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Capricor Therapeutics (NASDAQ: CAPR) plans to release its financial results for the third quarter of 2024 on November 13, 2024, followed by a conference call and webcast. The company is known for developing cell and exosome-based therapies for rare diseases, with its lead candidate, deramiocel, currently in Phase 3 trials for Duchenne muscular dystrophy. The event will allow management to update stakeholders on financial performance and corporate developments. Capricor's focus includes leveraging their innovative technologies to create transformative treatments.
Read more →CAPRCapricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Capricor Therapeutics has successfully closed its underwritten public offering, selling 5,073,800 shares and raising about $86.3 million. The offering included the full exercise of underwriters' option to purchase additional shares. The proceeds will support ongoing development and general corporate purposes. The offering was registered under an effective shelf registration statement with the SEC.
Read more →CAPR▼ -9.8%on this newsshared move
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Capricor Therapeutics has announced the pricing of a public offering of 4,412,000 shares of common stock at $17.00 per share, aiming to raise approximately $75 million. The offering is set to close on October 18, 2024, and the proceeds will primarily support the development and manufacturing of its product candidates. The company has also granted underwriters an option to purchase additional shares, potentially increasing the offering size. Capricor’s primary focus is on advancing its lead product candidate, deramiocel, for Duchenne muscular dystrophy.
Read more →CAPRCapricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Capricor Therapeutics announced positive long-term safety and efficacy data for deramiocel, its lead asset for treating Duchenne muscular dystrophy (DMD), during the World Muscle Society Congress. The data highlighted significant improvements in cardiac function, including left ventricular ejection fraction, over a three-year treatment period. The company plans to submit a Biologics License Application to the FDA by the end of 2024, which aims to expedite deramiocel's approval for DMD cardiomyopathy. Overall, the results indicate a robust therapeutic potential for patients suffering from DMD.
Read more →CAPR▼ -10.5%on this newsshared move
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -Company Plans to Complete Rolling BLA
Capricor Therapeutics has announced the initiation of its rolling submission of a Biologics License Application (BLA) with the U.S. FDA for deramiocel, a therapy aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy. The company plans to complete this submission by the end of 2024 and is optimistic about potential priority review eligibility due to the significant therapeutic improvements deramiocel may offer. This marks a significant milestone in the regulatory process towards bringing a first-in-class treatment to market, as there are currently no approved therapies for this severe condition. Capricor's efforts are supported by prior designations that enhance their path toward regulatory approval.
Read more →CAPR▲ +26.8%on this newsshared move
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
Capricor Therapeutics has announced the presentation of long-term safety and efficacy data from its HOPE-2 open-label extension study at the upcoming 2024 World Muscle Society Congress. The results will feature the lead asset, deramiocel, focusing on its benefits for treating Duchenne muscular dystrophy. This information is critical as Capricor prepares to file a Biologics License Application for deramiocel aimed at patients with DMD-cardiomyopathy. The presentation highlights the company's dedication to transformative therapies in rare diseases.
Read more →CAPR▲ +52.4%on this news· ran to +73% by day 1
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy -BLA to be Supported by Existing and Natural Hi
Capricor Therapeutics has announced its intention to file a Biologics License Application (BLA) for deramiocel, aimed at treating Duchenne muscular dystrophy cardiomyopathy. The submission will be supported by existing cardiac data as confirmed in meetings with the FDA. Capricor plans to begin the rolling submission process in October 2024 and has established internal GMP manufacturing to aid this effort. Deramiocel, which has shown promise in prior clinical trials, may provide a much-needed treatment option for a condition that currently lacks approved therapies.
Read more →CAPR▲ +18.2%on this news· ran to +98% by day 3shared move
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Capricor Therapeutics is set to host an investor webcast on September 24, 2024, to provide an update on its Duchenne muscular dystrophy (DMD) program. This is part of their efforts following recent discussions with the FDA regarding regulatory updates. The company is advancing its lead product candidate, deramiocel (CAP-1002), through Phase 3 clinical trials for DMD, showcasing ongoing progress in treating this serious condition.
Read more →CAPR▲ +15.2%on this news
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy -Capricor to Receive $15 Million Equity Inve
Capricor Therapeutics announced a binding term sheet with Nippon Shinyaku to commercialize its lead asset, deramiocel, in Europe for treating Duchenne muscular dystrophy. Capricor will receive a $15 million equity investment and a $20 million upfront payment, with potential milestones totaling approximately $1.5 billion. This partnership aims to extend Capricor's cash runway into 2026 and signals a significant strategic expansion for their therapeutic offerings. The deal also enhances Capricor's ability to prepare for product launch and manufacturing scale-up in the European market.
Read more →CAPRCapricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Capricor Therapeutics has announced its participation in several upcoming investor and scientific conferences, including the H.C. Wainwright 26th Annual Global Investment Conference and the Exosome-Based Therapeutic Summit. During these events, the company will provide updates on its lead therapeutic candidate, deramiocel, which is currently in Phase 3 clinical development for Duchenne muscular dystrophy. The company aims to showcase its advancements in exosome technology and overall corporate progress to potential investors and industry peers.
Read more →CAPR▼ -9%on this news
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update -Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment o
Capricor Therapeutics reported its Q2 2024 financial results, highlighting a positive pre-BLA meeting with the FDA regarding deramiocel, their lead asset for Duchenne muscular dystrophy (DMD). The company announced full enrollment in the Phase 3 HOPE-3 trial, aiming to report top-line data in Q4 2024. Positive data from the HOPE-2 open-label extension trial further supports the safety and efficacy of deramiocel. However, the company also reported an increase in net losses and operating expenses, raising concerns about financial sustainability as they pursue partnerships to strengthen their position.
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
Capricor Therapeutics is scheduled to release its financial results for Q2 2024 on August 7, 2024, followed by a conference call at 4:30 p.m. ET. The company is focused on developing cell and exosome-based therapies for rare diseases, notably advancing its product candidate, deramiocel, through Phase 3 clinical trials for Duchenne muscular dystrophy. Additionally, Capricor has secured a commercialization agreement for deramiocel in the U.S. and Japan, pending regulatory approval.
Read more →CAPRCapricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
Capricor Therapeutics, a biotechnology company focused on treating rare diseases, is set to join the Russell 2000 and Russell 3000 Indexes effective July 1, 2024. This inclusion marks a significant milestone, reflecting the company's advancements in its therapeutic pipeline, particularly its lead program aimed at treating Duchenne muscular dystrophy. The addition to these respected indexes is expected to increase Capricor's visibility among investors and bolster its market position.
Read more →CAPRCapricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
Capricor Therapeutics announced positive results from the HOPE-2 open label extension study for its lead product deramiocel (CAP-1002) in treating Duchenne muscular dystrophy (DMD). Over three years, patients showed significant improvements in cardiac function and maintained skeletal muscle performance. The company is set to discuss options with the FDA for expediting the Biologics License Application filing. These results will be presented at the upcoming Parent Project Muscular Dystrophy annual conference.
Read more →CAPRCapricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics announced a scheduled Pre-BLA meeting with the FDA for its product deramiocel (CAP-1002), aimed at treating Duchenne Muscular Dystrophy (DMD). This meeting is set for the third quarter of 2024 and will focus on finalizing the BLA filing plans and establishing a rolling submission timeline. The company aims to expedite the process due to the significant unmet needs in treating DMD, with plans to present new data at the upcoming Parent Project Muscular Dystrophy conference. Deramiocel is currently in Phase 3 clinical development and is viewed as a potential anchor therapy for DMD patients.
Read more →CAPRCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Therapeutics announced a successful Type-B meeting with the FDA concerning its lead asset, CAP-1002, targeting Duchenne muscular dystrophy (DMD). The FDA's agreement to a pre-BLA meeting is based on the review of clinical results from the HOPE-2 and HOPE-2 OLE studies. Capricor plans to initiate a rolling BLA submission starting in the third quarter of 2024, which could expedite the regulatory process. The company anticipates presenting additional data at an upcoming conference, further supporting the efficacy of CAP-1002.
Read more →CAPRCapricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics announced positive results from the HOPE-2 open-label extension study, showing sustained benefits of CAP-1002 in treating Duchenne muscular dystrophy (DMD) over three years. Key findings include a significant reduction in Upper Limb Function decline and stabilization of cardiac function compared to an external comparator group. The company aims to further discuss these results at the upcoming Parent Project Muscular Dystrophy conference and is on track to announce results from its Phase 3 HOPE-3 pivotal trial in late 2024.
Read more →CAPRCapricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Da
Capricor Therapeutics has reported its first-quarter financial results for 2024, outlining progress in various initiatives. Notably, their Phase 3 HOPE-3 trial involving CAP-1002 for Duchenne muscular dystrophy (DMD) is fully enrolled, with top-line data expected in Q4 2024. The company is aligned with the FDA regarding Chemistry Manufacturing Controls, marking a significant milestone. Financially, Capricor noted an increase in revenues but also reported a larger net loss compared to the same period in the prior year.
Read more →CAPRCapricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Capricor Therapeutics announced that its StealthX™ exosome platform has been selected for oral presentation at the ASGCT 27th Annual Meeting. The presentation will focus on preclinical findings related to an exosome-based therapeutic approach for arginase-1 deficiency (ARG1-D). The results indicate the exosomes were effective in delivering the Arg1 protein and showed enzymatic activity, suggesting potential for an enzyme replacement therapy. This reflects Capricor's broader commitment to developing innovative treatments for rare diseases.
Read more →CAPRCapricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
Capricor Therapeutics (NASDAQ: CAPR) has announced its participation in several upcoming scientific and medical conferences, including the ASGCT Annual Meeting and the PPMD Cardiac Workshop. The company will present research focusing on the therapeutic potential of its lead product candidate, CAP-1002, as well as advancements in exosome technology for rare diseases. The presentations aim to highlight Capricor's innovations in treating conditions such as Duchenne muscular dystrophy. Following the meetings, the related abstracts will be published on the Capricor website.
Read more →CAPRCapricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Capricor Therapeutics plans to release its financial results for the first quarter of 2024 after market close on May 13, 2024. Following the release, management will host a conference call and webcast to discuss the results and corporate developments. The company is currently advancing its lead therapy, CAP-1002, through Phase 3 trials for Duchenne muscular dystrophy, and is also developing exosome-based therapies. This update illustrates Capricor's commitment to innovation in rare disease treatments.
Read more →CAPRx4;Ɖƌŝů​Ϯϵ͕​ϮϬϮϰ EĂƐĚĂƋ͗​ WZ WͲϭϬϬϮ​&#
x4;Ɖƌŝů​Ϯϵ͕​ϮϬϮϰ EĂƐĚĂƋ͗​ WZ WͲϭϬϬϮ​D​WƌŽŐƌĂ
Read more →CAPRCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Capricor Therapeutics has reported a positive outcome from a Type-B meeting with the FDA concerning its lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy. The FDA has indicated support for Capricor's plan to submit a rolling Biologics License Application (BLA), which could accelerate the regulatory approval process. Capricor is also prepared to present three-year safety and efficacy data from its HOPE-2 clinical trial by Q2 2024. The alignment with the FDA on manufacturing comparability enhances Capricor's capability to utilize its San Diego facility for production after potential approval.
Read more →CAPRCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Capricor Therapeutics presented the positive 24-month results from its HOPE-2 open-label extension study for CAP-1002 at the 2024 MDA Conference. The study highlighted a 64% reduction in disease progression for patients with Duchenne muscular dystrophy (DMD) treated with CAP-1002 compared to placebo. Additionally, 67% of treated patients showed improvements in cardiac function. The ongoing study indicates a favorable safety profile and suggests the potential for continued long-term benefits of CAP-1002.
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update -Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystroph
Capricor Therapeutics has announced its fourth quarter and full year 2023 financial results, highlighting key milestones in its CAP-1002 program for Duchenne muscular dystrophy (DMD). The company successfully completed enrollment in Cohort A of the Phase 3 HOPE-3 trial and reported positive interim results. A meeting with the FDA is planned for Q1 2024 to discuss the BLA pathway for CAP-1002. Capricor's financial performance improved significantly, with a substantial revenue increase reported in the fourth quarter of 2023.
Read more →CAPR▲ +9.6%on this newsshared move
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics announced an upcoming in-person Type-B meeting with the FDA to discuss commercial manufacturing plans for CAP-1002, aimed at expediting its Biologics License Application (BLA) pathway for Duchenne muscular dystrophy. The meeting is set for late March, where CMC plans will be reviewed to accelerate potential commercialization. Capricor has previously secured RMAT and orphan drug designations, facilitating closer collaboration with the FDA. This follows the full enrollment of their Phase 3 trial, HOPE-3, with anticipated data release by the end of the year.
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
Capricor Therapeutics, a biotechnology company, will present its financial results for Q4 and the full year of 2023 after market close on February 29, 2024. Following the release, the management will host a webcast and conference call. Capricor is focused on developing cell and exosome-based treatments, notably advancing its lead candidate, CAP-1002, through Phase 3 clinical development for Duchenne muscular dystrophy. The company has partnered for the commercialization of CAP-1002 in the U.S. and Japan pending regulatory approval.
Read more →CAPR▲ +6.4%on this newsshared move
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
Capricor Therapeutics has announced a scale-up in the manufacturing of CAP-1002 at a new facility in San Diego, which is expected to enhance production capabilities for commercial use pending regulatory approval. The company also reported that Cohort B of the HOPE-3 Phase 3 clinical trial is enrolling quickly, with full enrollment anticipated by the second quarter of 2024. As the first cohort is fully enrolled, Capricor plans to meet with the FDA to explore potential expedited pathways to approval following the upcoming topline data readout.
Read more →CAPRCapricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Capricor Therapeutics has announced a collaboration with the National Institutes of Health (NIH) to advance its StealthX™ exosome-based multivalent vaccine for SARS-CoV-2. This vaccine, which has been selected as part of Project NextGen, aims to provide enhanced protection against COVID-19. The NIH will oversee a Phase 1 clinical trial for the vaccine, pending regulatory approval. Capricor's CEO emphasized the significance of this partnership in showcasing the potential of their exosome platform technology, which could also extend to treating other infectious diseases in the future.
Read more →CAPRCapricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis --Favorable Interim Futility Analysis Results-- --Successfu
Capricor Therapeutics has announced the continuation of its Phase 3 HOPE-3 trial of CAP-1002, following a positive interim futility analysis. This outcome supports the advancement of the trial for Duchenne muscular dystrophy (DMD) treatment and triggers a milestone payment from Nippon Shinyaku. Enrollment for the trial's Cohort B has begun, with topline data expected in the fourth quarter of 2024. The company plans to engage with the FDA to explore expedited approval opportunities for CAP-1002.
Read more →CAPR▲ +6%on this news
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update -Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Repor
Capricor Therapeutics has announced its third quarter 2023 financial results and provided a corporate update. The company successfully completed targeted enrollment for the HOPE-3 Phase 3 trial of CAP-1002, aimed at treating Duchenne muscular dystrophy. Positive feedback from the FDA regarding key clinical and regulatory requirements boosts the prospects for CAP-1002's development, with an interim futility analysis expected in the fourth quarter of 2023. Despite a net loss reported for this quarter, Capricor believes its financial resources are sufficient to cover anticipated expenses through 2025.
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
Capricor Therapeutics will present its third quarter 2023 financial results on November 14, 2023, followed by a conference call and webcast. The company is known for its focus on cell and exosome-based therapeutics, with its lead candidate, CAP-1002, in late-stage development for treating Duchenne muscular dystrophy. Furthermore, Capricor has partnered with Nippon Shinyaku Co. for exclusive commercialization rights to CAP-1002 in the U.S. and Japan. While the upcoming financial results are highly anticipated, investors should note the investigational status of its product candidates.
Read more →CAPRCapricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
Capricor Therapeutics is set to host a webinar in collaboration with Parent Project Muscular Dystrophy on October 25, 2023. The webinar will focus on the latest developments regarding the CAP-1002 program, which is currently in Phase 3 clinical trials for treating Duchenne muscular dystrophy. Participants will receive updates on regulatory matters and clinical progress. CAP-1002 is a significant candidate for Capricor as it seeks to address important medical needs in muscular disease therapy.
Read more →CAPRCapricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
Capricor Therapeutics presented promising data at the 28th Annual Congress of the World Muscle Society, highlighting the sustained efficacy and safety of its lead product, CAP-1002, for Duchenne muscular dystrophy (DMD) over a 24-month period. The study reported a significant reduction in disease progression compared to placebo, along with notable improvements in cardiac function among treated patients. Furthermore, Capricor's StealthX™ technology was showcased for its potential to enhance the delivery of antisense oligonucleotides. The company remains focused on advancing these therapies and completing enrollment for its HOPE-3 Phase 3 study.
Read more →CAPR▼ -41.2%on this news
Capricor Therapeutics Announces $23 Million Registered Direct Offering
Capricor Therapeutics announced a $23 million registered direct offering involving the sale of 4,935,621 shares of common stock with accompanying warrants. The offering, expected to close by October 3, 2023, aims to fund the company's research and development, product manufacturing, and general corporate purposes. The shares are sold as part of a shelf registration statement effective since June 2021. Capricor is recognized for its development of transformative cell and exosome-based therapeutics, especially its lead candidate, CAP-1002, targeting Duchenne muscular dystrophy.
Read more →CAPR▼ -41.2%on this news
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy -FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms C
Capricor Therapeutics recently announced a positive Type-B meeting with the FDA concerning its lead asset, CAP-1002, aimed at treating Duchenne muscular dystrophy. The FDA provided feedback confirming the current design and timeline for the HOPE-3 Phase 3 trial, which is essential for filing a Biologics License Application (BLA). The company is on schedule to complete the trial enrollment and anticipates sharing results from an interim analysis by the end of 2023. Additionally, CAP-1002 has received Orphan Drug Designation and RMAT status, supporting its regulatory pathway.
Read more →CAPRCapricor Therapeutics Appoints Michael Kelliher to Board of Directors
Capricor Therapeutics has appointed Michael Kelliher to its Board of Directors, effective immediately. Kelliher, who has extensive experience in business development and strategy from his time at Horizon Therapeutics, is expected to aid in driving Capricor's strategic initiatives, particularly for its late-stage clinical program for CAP-1002 aimed at treating Duchenne muscular dystrophy. The company's CEO expressed optimism about Kelliher's contributions during this critical phase for Capricor's growth. Kelliher also highlighted his commitment to advancing new therapies that could significantly impact patients' lives.
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update -Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment
Capricor Therapeutics reported its financial results for Q2 2023 and provided updates on its clinical programs, specifically CAP-1002 for Duchenne Muscular Dystrophy. The company shared positive two-year data from the HOPE-2 study and is on schedule to complete enrollment for the HOPE-3 trial by the end of 2023. Additionally, Capricor is progressing towards a potential Biologics License Application submission following discussions with the FDA. Despite reported increased operating expenses and a net loss, the company expressed optimism about future milestones and ongoing partnerships.
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
Capricor Therapeutics plans to present its financial results for the second quarter of 2023 and update on corporate developments on August 7. The webcast will occur at 4:30 p.m. ET, following the announcement after market close. The company is noted for its work on CAP-1002 for Duchenne muscular dystrophy and its advancements in exosome-based therapeutics. The presentation aims to provide insights into the company’s progress and future plans.
Read more →CAPRCapricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
Capricor Therapeutics has appointed Philip J. Gotwals, Ph.D., to its Board of Directors, effective immediately. Dr. Gotwals brings nearly 30 years of experience in biotechnology, notably from his role at Novartis Institutes for Biomedical Research. His expertise in drug development and business strategy is expected to support Capricor's initiatives, particularly in advancing their lead candidate, CAP-1002, for Duchenne muscular dystrophy. The company is also developing a novel exosome platform with diverse therapeutic applications.
Read more →CAPRCapricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors -John Hopkins School of Medicine Clinical Director Joins Capricor's Board of Directors with over 30 Years of Internal Medicine
Capricor Therapeutics has appointed Dr. Paul Auwaerter, Clinical Director at Johns Hopkins School of Medicine, to its Board of Directors. Dr. Auwaerter's extensive experience in internal medicine and infectious diseases is anticipated to bolster Capricor's drug development capabilities. His involvement comes at a critical time as the company advances its promising CAP-1002 cell therapy program for Duchenne muscular dystrophy. This strategic appointment reflects Capricor's commitment to enhancing its therapeutic pipeline.
Read more →CAPRCapricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics announced promising results from a 24-month extension study of CAP-1002 for Duchenne muscular dystrophy (DMD). The study showed that the majority of patients experienced improvements in left ventricular ejection fraction (LVEF), indicating preserved cardiac function, alongside significant benefits in skeletal muscle functionality. The safety profile of CAP-1002 remains favorable, positioning it as a potential key treatment option for DMD patients. Results will be presented at the Parent Project Muscular Dystrophy Annual Conference.
Read more →CAPRCapricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics announced that it will present 24-month safety and efficacy results from its ongoing HOPE-2 study of CAP-1002 for Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy Annual Conference. This important event will take place from June 29 to July 1, 2023, in Dallas, Texas, and aims to highlight the latest research and developments within the DMD community. Dr. Linda Marbán, the CEO, will provide the update during a key session of the conference.
Read more →CAPRCapricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics has announced a Type-B clinical meeting with the FDA scheduled for early Q3 2023 to discuss its CAP-1002 candidate for treating Duchenne muscular dystrophy (DMD). The meeting will focus on Capricor's pathway towards a potential Biologics License Application and further details on the ongoing HOPE-3 clinical trial. The company aims to complete patient enrollment in HOPE-3 in the second half of 2023 and plans to report interim analysis results later this year. Both the RMAT and Orphan Drug Designations provide additional support for CAP-1002's regulatory pathway.
Read more →CAPRCapricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update -Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); O
Capricor Therapeutics announced its financial results for Q1 2023 and provided a corporate update, highlighting progress in enrollment for the Phase 3 HOPE-3 trial of CAP-1002 in Duchenne Muscular Dystrophy. The company anticipates presenting 24-month data from the HOPE-2 study in Q2 2023, with plans for an interim analysis in Q4 2023. Financially, Capricor reported a net loss of approximately $7.8 million, though its cash position improved, totaling about $45.2 million as of March 31, 2023. The company is working closely with the FDA while also exploring potential partnerships for CAP-1002.
Read more →CAPRCapricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
Capricor Therapeutics announced it will release its first quarter 2023 financial results on May 11, followed by a conference call and webcast. The company focuses on developing cell and exosome-based therapies aimed at treating muscular diseases, with its lead candidate, CAP-1002, currently in late-stage clinical development. This event will provide investors insights into the firm's financial performance and strategic direction. However, the status of their investigational drugs remains unapproved, highlighting potential risks in their development pipeline.
Read more →CAPRCapricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
Capricor Therapeutics announced the publication of a preclinical study in Microbiology Spectrum, demonstrating the therapeutic potential of its StealthX™ platform for developing a multivalent vaccine against SARS-CoV-2. The study showed that engineered exosomes expressing spike and nucleocapsid proteins induced potent immune responses and a favorable safety profile in animal models. Capricor's CEO, Linda Marbán, expressed optimism about the technology's potential and the prospect of expanding their pipeline and partnerships based on the encouraging findings.
Read more →CAPRCapricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Capricor Therapeutics presented the results from its HOPE-2 study involving CAP-1002 for Duchenne muscular dystrophy (DMD) at the 2023 MDA Conference. The findings indicate a statistically significant improvement in upper limb performance among patients treated with CAP-1002 compared to those who received a placebo. The study suggests ongoing treatment with CAP-1002 can preserve skeletal muscle function over time. Capricor is also moving forward with the HOPE-3 Phase 3 trial for further evaluation of this therapy.
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update -Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dys
Capricor Therapeutics has reported its financial results for the fourth quarter and full year of 2022, highlighting progress in its HOPE-3 Phase 3 clinical trial of CAP-1002 for Duchenne Muscular Dystrophy. The company secured an expanded partnership with Nippon Shinyaku, which includes an upfront payment of $12 million. Capricor also engaged in a Type-B CMC meeting with the FDA to discuss the Biologics License Application pathway. Despite increasing operational costs and a reported net loss, the company remains optimistic about its future milestones and funding opportunities.
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
Capricor Therapeutics is set to announce its fourth quarter and full year financial results for 2022 on March 15, 2023, followed by a conference call. The company continues to focus on its lead candidate, CAP-1002, which is in late-stage development for treating Duchenne muscular dystrophy. Additionally, Capricor is advancing its exosome technology for potential therapeutic applications. This presentation will likely provide stakeholders with updates on the company's financial health and strategic objectives.
Read more →CAPRCapricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award
Capricor Therapeutics has announced that its HOPE-2 study of CAP-1002 for treating Duchenne muscular dystrophy has won the 2023 Top Ten Clinical Research Achievement Award from the Clinical Research Forum. This award recognizes significant advancements in clinical research globally. The CEO highlighted the strong potential of CAP-1002 for patients in need, as well as the importance of continued efforts towards commercialization. The award will be presented on April 17, 2023, in Washington, D.C.
Read more →CAPR▲ +10.4%on this news
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan -Expands Partnership with Nippon Shinyaku
Capricor Therapeutics has announced a partnership with Nippon Shinyaku for the exclusive commercialization and distribution of its lead asset, CAP-1002, in Japan for treating Duchenne muscular dystrophy (DMD). The agreement includes an upfront payment of $12 million, potential milestone payments up to $89 million, and a significant share of revenue from product sales. This collaboration follows an earlier agreement in the U.S. and aims to leverage Nippon Shinyaku's established expertise in rare diseases. CAP-1002 has demonstrated clinical benefits in prior studies, positioning it as a key therapeutic option for DMD patients.
Read more →CAPRCapricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Capricor Therapeutics announced encouraging 18-month results from its HOPE-2 open-label extension study of CAP-1002 in patients with Duchenne muscular dystrophy. The data highlights statistically significant improvements in upper limb function as measured by the Performance of the Upper Limb (PUL 2.0) scale. The ongoing study continues to support the drug's potential for long-term benefits and disease modification. Capricor is preparing for a pivotal Phase 3 trial and remains committed to active monitoring of patient safety and performance.
Read more →CAPRCapricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
Capricor Therapeutics announced a webinar scheduled for January 25, 2023, to present 18-month data results from its HOPE-2 open-label extension trial of CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). The event, hosted in collaboration with Parent Project Muscular Dystrophy, will provide updates on the ongoing clinical study. CAP-1002, an allogeneic cardiac-derived cell therapy, is currently in late-stage development for DMD. Details regarding the webinar and how to access it have been provided in the announcement.
Read more →CAPRCapricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
Capricor Therapeutics announced a preclinical study publication focusing on its StealthX™ exosome platform for vaccine development against SARS-CoV-2. The research demonstrated that vaccine candidates STX-S and STX-N elicited significant immune responses, with capabilities for broader immunity using minimal protein doses. The findings suggest StealthX™ may serve effectively in vaccinology, with potential applications extending beyond COVID-19. Capricor looks to leverage this technology in future therapeutic developments and partnerships.
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update -Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-
Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update -Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Presented Positive One-Year Safety and Efficacy Results
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2022 Financial Results and Recent Corporate Update on November 10
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its fin
Read more →CAPRCapricor Therapeutics to Present One-Year Results from HOPE-2 Open Label Extension Study at World Muscle Society 2022
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update -First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update -First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open La
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its fin
Read more →CAPR▲ +5.3%on this news
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy -Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to En
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy -Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients- -HOPE-3 Builds on Positiv
Read more →CAPRHOPE - 2 Open Label Extension (1 - Year Data Results) Trial conducted by Capricor National PI: Craig McDonald, M.D. (UC Davis) NASDAQ:CAPR Developing Transformative Therapiesfrom Bench to BedsideCapricorTherapeutics, Inc
(UC Davis)-Coalition Duchenne-CureDuchenne-The Jett Foundation-Action Duchenne-MDA-Casimir-NS Pharma -Capricor's DMD Advisory Board-Cuixia Tian, M.D. (CCHMC)-Russell Butterfield, M.D. (University of Utah)-Richard Finkel, M.D. (Nemours Children's Hospital)-Joanne Janas, M.D. (Chil
Read more →CAPRCapricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)- -Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking Session at PPMD’s Annual Conference on Saturday June 25, 2022- -Principal Investigat
Read more →CAPR▲ +7.8%on this news
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the C
Read more →CAPRCapricor Therapeutics Appoints Xavier Avat as Chief Business Officer
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercia
Read more →CAPRCapricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Li
Read more →CAPRCapricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update -Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dys
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update -Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30.0 Mi
Read more →CAPRCapricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial
Read more →CAPR▼ -11.4%on this news
Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. L
Read more →CAPR▼ -32.2%on this newsshared move
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients
-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated- SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today th
Read more →CAPR▼ -9.5%on this news
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partne
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Dis
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financia
Read more →CAPRCapricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today the expan
Read more →CAPR▲ +21.6%on this news
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S. -Partnership Leverages Nippon Shinyaku
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S. -Partnership Leverages Nippon Shinyaku's Deep Experience in Drug Development for Rare Diseases an
Read more →CAPRCapricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Capricor’s Exosome-based mRNA Vaccine for SARS-CoV-2 -In-Vivo Preclinical Data Published in the Journal of Biological Chemistry- -Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N Protein which may Confer Longer Lasting Immunity- -Completing Non-Clinica
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update CAP-1002 - Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Pres
Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update CAP-1002 - Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Final Data at Late-Breakin
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
LOS ANGELES, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financia
Read more →CAPRCapricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002 -Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Up
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002 -Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)- -Additional Positive Endpo
Read more →CAPRCapricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 - - The Cell & Gene Meeting on the Mesa Annual Conference: October 13 - LOS ANGELES, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology com
Read more →CAPRCapricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
LOS ANGELES, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Li
Read more →CAPR▲ +5.6%on this newsshared move
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of dis
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update CAP-1002 - Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Foll
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update CAP-1002 - Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance- -Commencing Start-Up Activities for
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financi
Read more →CAPRCapricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
-Preclinical Data Demonstrates Capricor’s Exosome Product as an Antishock Therapeutic if Delivered Early -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NA
Read more →CAPRCapricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors LOS ANGELES, Calif., July 27, 2021 - Capricor Therapeutics ("Capricor" or "the Company") (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-ba
Read more →CAPRCapricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced
Read more →CAPRCapricor Therapeutics to Participate in BIO Digital 2021 Conference
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the
Read more →CAPRCapricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting
-Capricor’s Findings Support Expansion Across Multiple Therapeutic Targets- -Conference will be held virtually: May 18 – May 21- LOS ANGELES, May 18, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformat
Read more →CAPRCapricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update -- -Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Data for
Capricor Therapeutics Reports First Quarter Results and Provides Corporate Update -Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Data for Phase II INSPIRE Clinical Trial Expected -Plan to File IND for Multivalen
Read more →CAPRCapricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
--Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery-- LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosom
Read more →CAPRCapricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financi
Read more →CAPRCapricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio - Portfolio Will Now Include Exclusive Rights to Engineered Exosomes for
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio -Portfolio Will Now Include Exclusive Rights to Engineered Exosomes for Vaccines and Therapeutics- LOS ANGELES, CALIF., April 2
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vacc
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine- -Pipeline Expansion Underway Using Engineered Cel
Read more →CAPRCapricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- -Functional Enzyme Expression and Real-Time Imaging of mRNA Expression in Live Animals- -Platform for Advancing Clinical Development of Exosome
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
LOS ANGELES, March 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders will relea
Read more →CAPRCapricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
-Technology Licensed from Johns Hopkins University- -Patient Data Demonstrates Validity of Novel Imaging-Based Approach Furthering Capricor’s Platform Advancement- LOS ANGELES, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotec
Read more →CAPRCapricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology
Read more →CAPRCapricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to expand Capricor’s manufacturing capacity for potential late-stage clinical tri
Read more →CAPRCapricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
LOS ANGELES, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of
Read more →CAPRCapricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
- Data Expected Second Quarter 2021 - - The INSPIRE Trial Is Designed to Assess the Ability of CAP-1002 to Modulate the Cytokine Storm Associated With Severe COVID-19 - LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage b
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- -Novel
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- -Novel Vaccine Induced Long-Lasting Immunity to Multiple SARS
Read more →CAPRCapricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19 Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunit
Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19 Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Scheduling Pre-IND Meeting with FDA to Discuss Clini
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
LOS ANGELES, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today, that it will
Read more →CAPRCapricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
--Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based ther
Read more →CAPRCapricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today
Read more →CAPRCapricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 – – The Study Leverages Capricor’s Lead Asset, CAP-1002 Technology – LOS ANGELES, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Capricor Therap
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Prec
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exosome Platform for COVID-19 -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies- -Preclinical Data Shows Positive Antibody CAP-1002 for COVI
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
LOS ANGELES, July 30, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that it will r
Read more →CAPRCapricor to Participate in BIO Digital International Convention
Management to Host One-on-One Partnering Meetings Conference June 8-12, 2020 LOS ANGELES, June 04, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeu
Read more →CAPRCapricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
LOS ANGELES, May 26, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that Capricor
Read more →CAPRCapricor Q1 Earnings Call and Corporate Update 1
Capricor Q1 Earnings Call and Corporate Update 1 May 14, 2020 Earnings Call NASDAQ: CAPR Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and inten
Read more →CAPRCapricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Duchenne Muscular Dystrophy Program -Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-contro
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Duchenne Muscular Dystrophy Program -Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of
Read more →CAPRCapricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, today announced that it will
Read more →CAPRA Study of CAP - 1002 in Ambulatory and Non - Ambulatory Patients with Duchenne Muscular Dystrophy [HOPE - 2] 12 - month Top - Line Final Study Results 1
A Study of CAP - 1002 in Ambulatory and Non - Ambulatory Patients with Duchenne Muscular Dystrophy [HOPE - 2] 12 - month Top - Line Final Study Results 1 May 13, 2020 Conference Call NASDAQ: CAPR Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedsi
Read more →CAPRCapricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002 -One-Year Results from Randomized, Double-Blind, Placebo-Controlled S
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002 -One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL)
Read more →CAPRNew Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 -U.S. FDA Approves Company's Expanded Access Protocol to Treat Additional Patients
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 -U.S. FDA Approves Company's Expanded Access Protocol to Treat Additional Patients- ANGELES, Calif. April 29, 2020 -- Capricor Therapeutics ("Capricor") (NASDAQ: CAPR) a clini
Read more →CAPRCapricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
-To Provide Clinical Development Update on CAP-1002- -Final HOPE-2 Data Now Expected by Mid-Q2- LOS ANGELES, April 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological t
Read more →CAPRCapricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
-CAP-1002 Aims to Mitigate Severe Inflammatory Response Associated with COVID-19- -Expanded Access Protocol Submitted to FDA- LOS ANGELES, April 03, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development o
Read more →CAPRCapricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update -To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Poten
Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update -To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Confere
Read more →CAPRCapricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
LOS ANGELES, March 17, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today
Read more →CAPRCapricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside NASDAQ : CAPR Corporate & Investor Presentation March 2020 Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside NASDAQ : CAPR Corporate & Investor Presentation March 2020 Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside Forward - Looking Statements 2 Statements in thi
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
LOS ANGELES, March 11, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders will release
Read more →CAPRCapricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market LOS ANGELES, December 19, 2019 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatm
Read more →CAPRNASDAQ : CAPR Corporate & Investor Presentation December 2019
NASDAQ : CAPR Corporate & Investor Presentation December 2019 Forward - Looking Statements 2 Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discover
Read more →CAPRCapricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market LOS ANGELES, December 17, 2019 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatm
Read more →CAPRNASDAQ : CAPR Corporate & Investor Presentation November 2019
NASDAQ : CAPR Corporate & Investor Presentation November 2019 Forward - Looking Statements 2 Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discover
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at Wo
Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update Update on End of Phase Type-B Meeting with FDA Data from the HOPE-2 Clinical Trial Presented at World Muscle Society Host Conference Call and Webcast Today at 4:30 p.m. ET November
Read more →CAPRCapricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report
Read more →CAPRCapricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Call Scheduled for Thursday, October 24th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of
Read more →CAPRCapricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET-- LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASD
Read more →CAPRA Study of CAP - 1002 in Ambulatory and Non - Ambulatory Patients with Duchenne Muscular Dystrophy [HOPE - 2] Updated Results from the Interim Analysis Presented at the 24 th Inter
A Study of CAP - 1002 in Ambulatory and Non - Ambulatory Patients with Duchenne Muscular Dystrophy [HOPE - 2] Updated Results from the Interim Analysis Presented at the 24 th International Annual Congress of the World Muscle Society 1 October 7, 2019 Conference Call NASDAQ: CAPR
Read more →CAPRCapricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
LOS ANGELES, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announ
Read more →CAPRCapricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, annou
Read more →CAPRCapricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today
Read more →CAPRCapricor Therapeutics to Present at Upcoming Conferences
LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today anno
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m.
Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Results from HOPE-2 Interim Analysis Reported in July Conference Call and Webcast Today at 4:30 p.m. ET August 6, 2019 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnolog
Read more →CAPRCapricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6
LOS ANGELES, July 30, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report
Read more →CAPRCapricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
--Independent Data Safety Monitoring Board recommends to continue HOPE-2 study-- --Capricor to resume treating currently enrolled patients-- LOS ANGELES, July 25, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, today
Read more →CAPRCapricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
-- Conference Call Today at 1 PM ET/10 AM PT -- LOS ANGELES, July 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) announced positive results from its interim analysis in the HOPE-2 Trial on Monday. The public is invited to join Parent Project Muscular Dy
Read more →CAPRNASDAQ : CAPR HOPE - 2 Data Update Conference Call
NASDAQ : CAPR HOPE - 2 Data Update Conference Call July 15, 2019 Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discov
Read more →CAPRCapricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy --Interim Analysis Showed Statistically Significant Improvements in the Pe
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy --Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspirator
Read more →CAPRCapricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today LOS ANGELES, May 13, 2019 - Capricor Therapeutics (NASDAQ: CAPR)
Read more →CAPRCapricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today LOS ANGELES, March 28, 2019 - Capricor Therapeutics
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
LOS ANGELES, March 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will repor
Read more →CAPRCapricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy LOS ANGELES, February 6, 2019 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patie
Read more →CAPRCapricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA FDA Provides Positive Feedback on Design for HOPE-2 Clinical Trial
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA FDA Provides Positive Feedback on Design for HOPE-2 Clinical Trial LOS ANGELES, January 22, 2019 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today a
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update To Host Conference Call and Webcast Today at 4:30 p.m.
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update To Host Conference Call and Webcast Today LOS ANGELES, November 13, 2018 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development
Read more →CAPRCapricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) announced today that it will meet with the U.S. Food and Drug Administration (FD
Read more →CAPRCapricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action Duchenne International Conference, Capricor Therapeutics, Inc. (NASDAQ: CAPR) will presen
Read more →CAPRCapricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report
Read more →CAPRCapricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6
Presentation to Focus on Company’s Therapeutic Pipeline for Duchenne Muscular Dystrophy and other Rare Diseases LOS ANGELES, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a corporate overview of its research and development of cell and
Read more →CAPRCapricor Therapeutics to Participate in Upcoming Conferences
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc. (NASDAQ: CAPR), is presenting at two conferences, the BTIG Fall Biotechnology Confere
Read more →CAPRCapricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy, CAP-1002, which is currently in clinical development for the treatment of Duchenne mus
Read more →CAPRCapricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the mechanism of action and the immunomodulatory capacities of CAP-2003, the company’s i
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update To Host Conference Call and Webcast Today at 4:30 p.m.
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, August 9, 2018 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on t
Read more →CAPRCapricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9
LOS ANGELES, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report
Read more →CAPRCapricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic plat
Read more →CAPRCapricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information about the HOPE-2 clinical trial, which is evaluating the safety and efficacy of repea
Read more →CAPRCapricor Therapeutics to Present at PPMD Annual Conference
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular Dystrophy (PPMD) 2018 Annual Conference on June 29 in Scottsdale, AZ. PPMD 2018 Ann
Read more →CAPRCapricor Therapeutics to Present at the 2018 BIO International Convention in Boston
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders, today announced that Linda Marbán, Ph.D., its president and chief executive officer
Read more →CAPRCapricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m.
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update HOPE-2 Clinical Trial is Currently Enrolling Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage
Read more →CAPRCapricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10
LOS ANGELES, May 04, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report i
Read more →CAPRNASDAQ: CAPR May 2018 Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and r
NASDAQ: CAPR May 2018 Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discovery efforts and clinical trials ; the pace
Read more →CAPRCapricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at the plenary session of the International Society for Cellular Therapy (ISCT) 2018 Mo
Read more →CAPRCapricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test the safety and efficacy of Capricor’s novel cellular therapy, CAP-1002, in boys and
Read more →CAPRCapricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an increase in exercise performance in a disease model of Duchenne muscular dystroph
Read more →CAPRCapricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
LOS ANGELES, April 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will be among the companies providing presentations at the Alliance for Regenerative Medicine’s (ARM’s) annual Cell & Gene Therapy Investor Day on April 17 in New York City
Read more →CAPRCapricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
LOS ANGELES, March 21, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will participate in two upcoming investment banking conferences, Oppenheimer’s 28th Annual Healthcare Conference and the Needham & Company 17th Annual Healthcare Conference
Read more →CAPRCapricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update Planning to Initiate HOPE-2 Clinical Trial To Host Conference Call and Webcast Today at 4:30 p.m.
Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update Planning to Initiate HOPE-2 Clinical To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 14, 2018 - Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage bio
Read more →CAPRCapricor, Inc. KOL Lunch on DMD Key Opinion Leaders Lunch to discuss the emerging clinical paradigm in DMD focusing on gene and cell therapy.
Capricor, Inc. KOL Lunch on DMD Key Opinion Leaders Lunch to discuss the emerging clinical paradigm in DMD focusing on gene and cell therapy. March 9, 2018 NASDAQ: CAPR Capricor , Inc. KOL Lunch on DMD Forward - Looking Statements Statements in this presentation regarding the ef
Read more →CAPRCapricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
LOS ANGELES, March 08, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report
Read more →CAPRCapricor to Host Key Opinion Leader Lunch on March 9
LOS ANGELES, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it will host a Key Opinion Leader Lunch in New York City on March 9 featuring four distinguished speakers to discuss the emerging paradigms in gene and cellular therapies to treat D
Read more →CAPRCapricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
LOS ANGELES, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) will provide an update on HOPE-2, its trial for CAP-1002, the company’s lead investigational therapy for the treatment of Duchenne muscular dystrophy, at the 16th International Conference on Duchen
Read more →CAPRCapricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy CAP-1002 to Benefit from Expedited Review Program for Drugs for Unmet Needs
Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy CAP-1002 to Benefit from Expedited Review Program for Drugs for Unmet Needs LOS ANGELES, Feb. 5, 2018 - Capricor Therapeutics (NASDAQ: CAPR) today announced that th
Read more →CAPRCapricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies
LOS ANGELES, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells
Read more →CAPRNASDAQ: CAPR December 2017
NASDAQ: CAPR December 2017 Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discovery efforts and clinical trials ; the
Read more →CAPRCAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) ASSETS
CAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) ASSETS September 30, 2017 Pro-Forma Adjustments (1) Pro-Forma September 30, 2017 CURRENT ASSETS Cash and cash equivalents $ 8,897,087 $ 8,897,087 Marketable securities 4,99
Read more →CAPRCapricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002 Potential Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018 Company t
Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002 Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018 Host Conference Call and Webcast at 4:30 p.m. ET Today Nov. 29, 2017 - Capricor Ther
Read more →CAPRSignificant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy Dr. Ronald G. Victor Presents 12-Month Results of HOPE Clinical Trial at AHA Late-Breaking Se
Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy G. Victor Presents 12-Month Results of HOPE Clinical Trial at to Host Conference Call and Webcast Today at 4:30 p.m. ET - Nov. 15, 2017 - Boys and young men in ad
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program 12-Month Results from HOPE Clinical Trial to be Presented Next Week at AHA Potenti
Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program 12-Month Results from HOPE Clinical Trial to be Presented Next Week at AHA Potential Registration Trial Planned to Initiate in the First
Read more →CAPRCapricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress Data Set the Stage for the Upcoming HOPE-2 Clinical Trial of CAP-1002 SAINT MALO, FR
Therapeutics Presents Positive Six-Month Results in Muscular Dystrophy at World Muscle Society Data Set the Stage for the Upcoming HOPE-2 Clinical Trial of CAP-1002 SAINT MALO, FRANCE - (Oct. 4, 2017) - Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at
Read more →CAPRNASDAQ: CAPR October 2017 Capricor Therapeutics Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, co
NASDAQ: CAPR October 2017 Capricor Therapeutics Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and cl
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update Announced Statistically-Significant Improvements in Skeletal and Cardiac Muscle Function in Patients Treated with CAP-1002
Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update Announced Statistically-Significant Improvements in Skeletal and Cardiac Muscle Function in Patients Treated with CAP-1002 in the HOPE-Duchenne Trial Plans to Commence Clinical
Read more →CAPRCapricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option LOS ANGELES, July 6, 2017 - Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that Janssen Biotech, Inc. (Janssen) has decided not to exercise its option to
Read more →CAPRNASDAQ: CAPR June 2017 a translational m edicine c ompany
NASDAQ: CAPR June 2017 a translational m edicine c ompany 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discovery efforts and clinical trials ; th
Read more →CAPRCapricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update To Propose Registrational Strategy for Duchenne Muscular Dystrophy Indication to
Capricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update To Propose Registrational Strategy for Duchenne Muscular Dystrophy Indication to FDA LOS ANGELES, May 15, 2017 - Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced its fi
Read more →CAPRCapricor Therapeutics Provides Update on ALLSTAR Trial Unlikely to Achieve Primary Efficacy Endpoint of Change in Infarct Size in Patients Following Heart Attack Capricor to Focus on Potential Registration Program in Duc
Capricor Therapeutics Provides Update on ALLSTAR Trial Unlikely to Achieve Primary Efficacy Endpoint of Change in Infarct Size in Patients Following Heart Attack Capricor to Focus on Potential Registration Program in Duchenne Muscular Dystrophy Company to Hold Conference Ca
Read more →CAPRCapricor Therapeutics Announces Private Placement of Common Stock Investors Include Cedars-Sinai Medical Center and Select Board Members
Therapeutics Announces Private Placement of Common Stock Include Cedars-Sinai Medical Center and Select Board Members LOS ANGELES, May 8, 2017 - Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies f
Read more →CAPRCapricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy Statistically-Significant Improvements in Measures of Cardiac and Upper Limb Fu
Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy Statistically-Significant Improvements in Measures of Cardiac and Upper Limb Function in Patients Treated with CAP-1002 to Seek Breakth
Read more →CAPRNASDAQ: CAPR
NASDAQ: CAPR April 25, 2017 a translational m edicine c ompany Top - Line Six - Month Results of the HOPE - Duchenne Trial Conference Call to Discuss 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capr
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update To Report Top-Line Six-Month Results from the Randomized HOPE-Duchenne Clinical Trial in April 2017 Company
Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update To Report Top-Line Six-Month Results from the Randomized HOPE-Duchenne Clinical Trial in April 2017 Company to Host Conference Call and Webcast Today at 4:30 p.m.
Read more →CAPRCorporate Overview February 2017 A Translational Medicine Company NASDAQ: CAPR 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capricor Therape
Corporate Overview February 2017 A Translational Medicine Company NASDAQ: CAPR 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capricor Therapeutics, Inc . (Capricor) as well as assumptions made by and
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Completed Treatment in Phase I/II HOPE-Duchenne and Phase II ALLSTAR Clinical Trials of CAP-1002 Announced Planned Expansio
Capricor Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Completed Treatment in Phase I/II HOPE-Duchenne and Phase II ALLSTAR Clinical Trials Announced Planned Expansion of Clinical Program in Duchenne Muscular Dystrophy to Evaluate C
Read more →CAPRNASDAQ: CAPR A Translational Medicine Company www.capricor.com Investor Presentation October 2016 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management
NASDAQ: CAPR A Translational Medicine Company www.capricor.com Investor Presentation October 2016 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capricor Therapeutics, Inc . (Capricor) as well as assum
Read more →CAPRCapricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds Underwriters' Over-Allotment Option Fully Exercised
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds Underwriters' Over-Allotment Option Fully Exercised LOS ANGELES, September 21, 2016 - Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the closing of its
Read more →CAPRCapricor Therapeutics Announces Pricing of Offerings of Common Stock
Capricor Therapeutics Announces Pricing of Offerings of Common Stock LOS ANGELES, September 16, 2016 - Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the pricing of its offerings of 3,000,000 shares of its common stock at an offering price of $3.20 per share, befo
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update Duchenne Muscular Dystrophy Trial on Track to Report Top-Line Six-Month Results in the First Quarter of 2017 Six-Month Resu
Capricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update Duchenne Muscular Dystrophy Trial on Track to Report Top-Line Six-Month Results in the First Quarter of 2017 Six-Month Results of ALLSTAR to be Delivered to Janssen Biotech in th
Read more →CAPRNASDAQ: CAPR A Translational Medicine Company www.capricor.com Investor Presentation June 2016 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management of
NASDAQ: CAPR A Translational Medicine Company www.capricor.com Investor Presentation June 2016 2 This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capricor Therapeutics, Inc . (Capricor) as well as assumpti
Read more →CAPRCapricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference C
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 12, 2016 May 12, 2016 - Capricor
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update Awarded CIRM Grant of Approximately $3.4 Million to Support the Phase I/II HOPE-Duchenne Clinical Trial Six-Month Data
Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update CIRM Grant of Approximately $3.4 Million to Support the Phase I/II HOPE-Duchenne Clinical Trial Data from Phase II ALLSTAR Clinical Trial Expected to be Available in the First Quarter o
Read more →CAPRCapricor Therapeutics Announces $4 Million Registered Direct Offering
Capricor Therapeutics Announces $4 Million Registered Direct Offering March 15, 2016 - Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that it has en
Read more →CAPRCapricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial
Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial February 22, 2016 - Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on th
Read more →CAPRNASDAQ: CAPR December 2015 Transformative Therapies from Bench to Bedside 2 Forward - Looking Statements This presentation contains forward - looking statements and information that are based on the beliefs of the manage
NASDAQ: CAPR December 2015 Transformative Therapies from Bench to Bedside 2 Forward - Looking Statements This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capricor Therapeutics, Inc. (Capricor) as well as a
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights Positive Six-Month Safety and Efficacy Signals Reported for the DYNAMIC Clinical Trial at American Heart Association Scientific Sessions Co
Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights Six-Month Safety and Efficacy Signals Reported for the DYNAMIC Clinical Trial at American Heart Association Scientific Sessions Company to Host Conference Call and Webcast at 4:30 p.m. EST, Today
Read more →CAPRCapricor Therapeutics and CureDuchenne to Host Webinar on November 3, 2015 at 3:00 p.m. ET
LOS ANGELES, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics and CureDuchenne, a national nonprofit organization dedicated to finding a
Read more →CAPRCapricor Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
LOS ANGELES, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics announced today that Linda Marb n, Chief Executive Officer will present at
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights Company to Host Conference Call and Webcast at 4:30 p.m.
Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, August 13, 2015 August 13, 2015 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discove
Read more →CAPRCapricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT
LOS ANGELES, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases today announced that company management will h
Read more →CAPRCapricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer
LOS ANGELES, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced the appointment of Deborah D. Ascheim, M.D., to the positio
Read more →CAPRCapricor Therapeutics, Inc. (Nasdaq: CAPR) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, June 22, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases will visit the Nasdaq MarketSite in Times Squar
Read more →CAPRCapricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies
LOS ANGELES, June 17, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases today announced the appointment of Houman Hem
Read more →CAPRCapricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET
LOS ANGELES, June 15, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure
Read more →CAPRCapricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
LOS ANGELES, June 8, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its
Read more →CAPRCapricor Therapeutics to Participate in Two Upcoming Investor Conferences in June
LOS ANGELES, May 26, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it will be participating in two upcoming investor conferenc
Read more →CAPRCapricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights Company to Host Conference Call and Webcast at 4:30 p.m.
Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 12, 2015 May 12, 2015 -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on developing novel t
Read more →CAPRCapricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
LOS ANGELES, May 5, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that company management will hold a conference call to discuss fi
Read more →CAPRCapricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
LOS ANGELES, April 22, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has been granted orphan drug designation by the U.S. F
Read more →CAPRCapricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
LOS ANGELES, April 8, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of the initial phase of its DY
Read more →CAPRCapricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
LOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of its first Phase II clinica
Read more →CAPRCapricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
LOS ANGELES, March 23, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that Linda Marb n, Ph.D., Chief Executive Officer, will presen
Read more →CAPRCapricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
LOS ANGELES, March 18, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today provided a business and financial update for the fourth quarter and full
Read more →CAPRCapricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
LOS ANGELES, March 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that company management will hold a conference call to discuss
Read more →CAPRCapricor Therapeutics to Present at the 27th Annual ROTH Conference
LOS ANGELES, March 10, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Linda Marb n, Ph.D., Chief Executive Officer, is schedule
Read more →CAPRCapricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure
LOS ANGELES, March 5, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it is currently enrolling a Phase II clinical trial with Ce
Read more →CAPRCapricor Therapeutics Announces Uplisting to NASDAQ Capital Market NASDAQ trading of "CAPR" to commence on
Capricor Therapeutics Announces Uplisting to NASDAQ Capital Market NASDAQ trading of "CAPR" to commence on March 9, 2015 March 5, 2015 - Capricor Therapeutics, Inc. (OTCQB: CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovas
Read more →CAPRCapricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
LOS ANGELES, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Thomas Copmann, Ph.D., has been appointed to the newly crea
Read more →CAPRCAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
CONSOLIDATED BALANCE SHEETS September 30, 2014 Pro-Forma Adjustments Pro-Forma September 30, 2014 ASSETS CURRENT ASSETS Cash and cash equivalents $ 9,805,435 $ 17,052,029 (1) $ 26,857,464 Marketable securities 325,318 325,318 Restricted
Read more →CAPRCapricor Therapeutics Announces $7 Million Private Placement of Common Stock Institutional Investors include: Broadfin Capital, LLC and Sabby Capital
Therapeutics Announces $7 Million Private Placement of Institutional Investors include: Broadfin Capital, LLC and Sabby Capital, LLC February 4, 2015 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on developing novel therapeutics for the treatmen
Read more →CAPRCapricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure f
Read more →CAPRCapricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the first three patients have been treated in its DYNAMIC c
Read more →CAPRCapricor Therapeutics Announces $10 Million Private Placement of Common Stock Investors include: Cedars-Sinai Medical Center, CureDuchenne Ventures LLC, Select Board Members and Capricor Management
Capricor Therapeutics Announces $10 Million Investors include: Cedars-Sinai Medical Center, CureDuchenne Ventures LLC, Select Board Members and Capricor Management January 12, 2015 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on developing nove
Read more →CAPRCapricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marb n will deliver an overview of C
Read more →CAPRCapricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced yesterday at the American Heart Association's Annual Scientific Sessio
Read more →CAPRCapricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy Capricor Intends to File for Approval to Conduct Clinical Trial of CAP-1002 i
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy Capricor Intends to File for Approval to Conduct Clinical Trial of CAP-1002 in Duchenne Cardiomyopathy LOS ANGELES, November 18, 20
Read more →CAPRCapricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights Announced Plans for Cenderitide Clinical Program and Clinical Program for Duchenne Muscular Dystrophy Conference call scheduled for Wednesd
Therapeutics Reports Third Quarter 2014 & Business Highlights Plans for Cenderitide Clinical Program and Clinical Program for call scheduled for Wednesday, November 12, 2014 (4:30 p.m. EST) November 12, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (CAPR), a biotechnol
Read more →CAPRCapricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
LOS ANGELES, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the Company will hold a conference call to discuss the data
Read more →CAPRTransformative Therapies from Bench to Bedside Corporate Presentation November 2014 Non - confidential Clinical - stage biotechnology company developing novel therapeutics for the treatment of cardiovascular diseases Tic
Transformative Therapies from Bench to Bedside Corporate Presentation November 2014 Non - confidential Clinical - stage biotechnology company developing novel therapeutics for the treatment of cardiovascular diseases Ticker: CAPR Forward Looking Statements This presentation cont
Read more →CAPRCapricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
LOS ANGELES, Oct. 31, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Company management will hold a conference call to discuss t
Read more →CAPRCapricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides from Medtronic, Inc.
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides from Medtronic, Inc. LOS ANGELES, October 14, 2014 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on developing novel therapeutics for th
Read more →CAPRCapricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
LOS ANGELES, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for
Read more →CAPRCapricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy with Cardiosphere-Derived Cells (CDCs)
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy with Cardiosphere-Derived Cells (CDCs) October 6, 2014 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on developing novel therapeutics for the tre
Read more →CAPRCapricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014 September 18, 2014 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseas
Read more →CAPRCapricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights Reports Encouraging Results from Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License with Cedars-Sinai Medical Center for E
Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights Reports Encouraging Results from Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License with Cedars-Sinai Medical Center for Exosomes IP Portfolio Conference call scheduled for Wedn
Read more →CAPRCapricor Therapeutics to Hold Second Quarter 2014 Business Update Conference Call on August 13, 2014 at 4:30 p.m. Eastern Time
LOS ANGELES, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced that Company management will hold a conference call to discuss second quart
Read more →CAPRCapricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway CNN Airs Story Showcasing Capricor's ALLSTAR Clinical Trial
Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway CNN Airs Story Showcasing Capricor's ALLSTAR Clinical Trial LOS ANGELES, July 16, 2014 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on developing novel
Read more →CAPRCapricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention
LOS ANGELES, June 23, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Linda Marb n, President and CEO, will present during a
Read more →CAPRCapricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting
LOS ANGELES, June 19, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Dr. Rachel Ruckdeschel Smith, Ph.D., Vice President of Rese
Read more →CAPRCapricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations
Identifies Exosomes Originating From Cardiosphere-Derived Cells (CDCs) as Key Mediators of Myocardial Regeneration Highlights Potential Utility of Exosomes as Cell-Free Therapeutic Candidate LOS ANGELES, May 28, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR),
Read more →CAPRCapricor Therapeutics Reports First Quarter 2014 Business Highlights
Signs Collaboration Agreement With Janssen Biotech; Initiates Phase II Clinical Study of CAP-1002 Conference Call Scheduled for Thursday May 15, 2014 at 4:30 p.m. Eastern Time LOS ANGELES, May 15, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnolo
Read more →CAPRCapricor Therapeutics to Hold First Quarter 2014 Business Update Conference Call on May 15, 2014 at 4:30 p.m. Eastern Time
LOS ANGELES, May 14, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced that Company management will hold a conference call to discuss first quarte
Read more →CAPRCapricor Therapeutics Enters into Exclusive License with Cedars-Sinai Medical Center for Exosome-related IP Portfolio Provides Potential for Broad Regenerative Medicine Therapeutic Platform
Capricor Therapeutics Enters into Exclusive Cedars-Sinai Medical Center for Exosome-related Provides Potential for Broad Regenerative Medicine Therapeutic Platform LOS ANGELES, May 6, 2014 - Capricor Therapeutics, Inc. (OTCBB: CAPR), a biotechnology company focused on develo
Read more →CAPRCapricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
LOS ANGELES, March 28, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marb n, M.
Read more →CAPRCapricor Therapeutics to Present at Two Upcoming Investor Conferences
LOS ANGELES, March 10, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that Chief Executive Officer Dr. Linda Marb n is scheduled to present at the 26th Annual ROTH Conference, being held March 9-12, 2014 in Dana Point, Calif., and the Alliance f
Read more →CAPRDECEMBER 31, 2012 AND 2011
FINANCIAL STATEMENTS DECEMBER 31, 2012 AND 2011 (A DEVELOPMENT STAGE COMPANY) PAGE INDEPENDENT AUDITORS' REPORT 1 BALANCE SHEETS 2 STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 3 STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) 4 - 6 STATEMENTS OF CASH FLOWS 7
Read more →CAPRCapricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
LOS ANGELES, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed t
Read more →CAPRCapricor and Nile Therapeutics Complete Merger to Form Capricor Therapeutics, Inc. Common Stock to Begin Trading under Symbol NLTXD Capricor to Present at Piper Jaffray 25 th Annual Healthcare Conference LOS ANGELES and
Capricor and Nile Therapeutics Complete Merger to Form Capricor Therapeutics, Inc. Common Stock to Begin Trading under Symbol Capricor to Present at Piper Jaffray 25th Annual Healthcare Conference LOS ANGELES and SAN MATEO, Calif., November 21, 2013 -- Capricor, Inc. and Ni
Read more →CAPRCapricor and Nile Therapeutics Announce Merger Agreement Capricor Therapeutics, Inc. will emerge from transaction as new public company with a diversified cardiovascular therapeutic pipeline LOS ANGELES and
Capricor and Nile Therapeutics Announce Capricor Therapeutics, Inc. will emerge from transaction as new public company with a diversified cardiovascular therapeutic pipeline LOS ANGELES and SAN MATEO, Calif., July 8, 2013 /PRNewswire/ - Capricor, Inc., a privately held biotec
Read more →CAPRNile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director SAN MATEO, CA, August 6, 2012 -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has
Read more →CAPRNile Therapeutics, Inc. To Raise $2.5 Million in Private Placement
Nile Therapeutics, Inc. To Raise $2.5 Million in Private Placement SAN MATEO, CA, June 21, 2011 - Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive
Read more →CAPRPRESS RELEASE
Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease SAN MATEO, CA, February 28, 2011 -- Nile Therapeutics, Inc. (NASDAQ: NLTX), a company focused on the development of novel therapeutics for heart failure pat
Read more →CAPRB.
B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of SAN MATEO, CA, July 22, 2010 - Nile Therapeutics, Inc. (NASDAQ: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced the appointm
Read more →CAPRNile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives SAN FRANCISCO, March 18 Nile Therapeutics, Inc. (Nasdaq: NLTX News), a leading company
Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives SAN FRANCISCO, March 18 Nile Therapeutics, Inc. (Nasdaq: NLTX News), a leading company in the development of novel therapeutics for heart failure patients, tod
Read more →CAPRNile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program SAN FRANCISCO, Jan. 20 Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that it will focus resources on the dev
Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program SAN FRANCISCO, Jan. 20 Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that it will focus resources on the development of its natriuretic peptide franchise, including C
Read more →CAPRNile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure SAN FRANCISCO, Dec. 9 Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced prelimina
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure FRANCISCO, Dec. 9 Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced preliminary data from its recently completed multi-center, open-label, a
Read more →CAPRNile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure SAN FRANCISCO, Oct. 14 Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced interim data from its multi-cen
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure SAN FRANCISCO, Oct. 14 Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced interim data from its multi-center, open-label Phase 2a clinical study of CD-NP, a novel
Read more →CAPRNile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results on Thursday
Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results on Thursday March 13, 2008 March 13, 2008 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB), today announced the fourth quarter and full year financial results for 2007. Par
Read more →CAPRHsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics Monday February 25, 9:00 am ET BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (OTC Bulletin Board:
Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics Monday February 25, 9:00 am ET BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB - News), a biopharmaceutical company focused on developing the
Read more →CAPRNile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP BERKELEY, Calif., Feb. 6 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that the fi
Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP BERKELEY, Calif., Feb. 6 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that the first heart failure patient has been dosed in its Phase Ib,
Read more →CAPRNile Therapeutics Appoints Pedro Granadillo to Board of Directors
Nile Therapeutics Appoints Pedro Granadillo to Board of Directors BERKELEY, Calif., Oct. 18, 2007 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (OTCBB: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, announced today that Mr. Pe
Read more →CAPRNile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ Nile Therapeutics, Inc
Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ Nile Therapeutics, Inc. (BULLETIN BOARD: NILT), today announced results from a Ph
Read more →CAPRNile Therapeutics, Inc. Completes $20 Million Financing and Reverse Merger with SMI Products, Inc. Private offering provides new funding as Nile Therapeutics, Inc. becomes a publicly reporting company. BERKELEY, Calif.,
Therapeutics, Inc. Completes $20 Million Financing and Reverse Merger with offering provides new funding as Nile Therapeutics, Inc. becomes a publicly Calif., Sept. 18 -- Nile Therapeutics, Inc. ("Nile"), a biopharmaceutical company focused on developing therapies for cardiova
Read more →Competitive Position
How CAPR ranks across every disease it competes inCompetitive Position is a premium feature
See how CAPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial